What Has Been the Growth of the Eye Melanoma Market So Far?
The eye melanoma market has seen considerable growth due to a variety of factors.
• In recent years, the market size for eye melanoma has seen substantial growth. It's predicted that it will rise from $9.1 billion in 2024 to $9.89 billion in 2025, boasting a compound annual growth rate (CAGR) of 8.7%.
Factors contributing to this growth during the historical period include heightened awareness and early detection, an aging population along with sun exposure, an increase in the incidence of skin cancer, the evolution of targeted therapies, and the role of patient advocacy and support programs.
What Is the Forecasted Market Size and Growth Rate for The Eye Melanoma Market Size In The Coming Years?
The eye melanoma market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for eye melanoma is forecasted to witness significant expansion in the upcoming years. The growth is projected to reach $13.77 billion by 2029, growing at a compound annual growth rate (CAGR) of 8.6%.
This anticipated growth over the forecast period is primarily due to ongoing public health campaigns, research in genetic and molecular profiling, and the worldwide trend of an aging population. Key trends to watch during the forecast period include the incorporation of artificial intelligence (AI), the emergence of targeted therapies, a focus on rare disease drug development, patient-oriented drug approval methods, progress in diagnostic imaging, advances in treatment methodologies, and technological breakthroughs in imaging.
What Factors Are Driving Growth In The Eye Melanoma Market?
The rise in the number of eye cancer cases is predicted to fuel the expansion of the eye melanoma market. Eye cancer involves the unregulated growth of dysfunctional cells within the eye's structures. Increased detection, awareness, and advancements in treatment methodologies have led to the identification and management of early-stage diseases, thereby contributing to an increased demand for specialized therapies and interventions. The American Cancer Society, a US-based non-profit organization, noted a 5.12% rise in eye and orbital cancer cases to 3,490 in 2023, up from 3,320 cases in 2021. Hence, the escalating prevalence of eye cancer is anticipated to steer the growth of the eye melanoma market.
Eye Melanoma Market Driver: An Uptick in the Elderly Population Boosts Eye Melanoma Market Growth
What Are The Main Segments Of The Global Eye Melanoma Market?
The eye melanoma market covered in this report is segmented –
1) By Site: Uvea, Sclera, Retina
2) By Diagnosis: Imaging, Biopsy, Eye Exam
3) By Treatment: Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Other Treatment
4) By End User: Hospitals And Clinics, Academic Institutes
Subsegments:
1) By Uvea: Choroid Melanoma, Ciliary Body Melanoma, Iris Melanoma
2) By Sclera: Scleral Melanoma
3) By Retina: Retinal Melanoma
Pre-Book The Eye Melanoma Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Eye Melanoma Market?
Leading companies in the eye melanoma treatment industry are concentrating their efforts on creating novel and targeted treatments, such as immunotherapies, to improve patient outcomes and enhance their quality of life. These groundbreaking treatment approaches have recently made their debut in the world of oncology. For example, in January 2022, Immunocore Ltd., a UK-based biopharmaceutical firm concentrating on the R&D of biological drugs via soluble T-cell receptor technology, received the green light from the U.S. Food and Drug Administration (FDA) for Kimmtrak (tebentafusp-tabn). It's a T-cell receptor therapeutic and a first-of-its-kind treatment for patients with inoperable or metastasized uveal melanoma (mUM). Kimmtrak is an immunotherapy that zeroes in on a particular protein named gp100 found on the surface of uveal melanoma (UM) cells. It kickstarts the patient’s immune system to eradicate melanoma by interaction with specific immune cells through engineered T-cell receptors, proposing a precision-focused approach to combating cancer.
Who Are the Key Players In The Eye Melanoma Market?
Major companies operating in the eye melanoma market report are:
• Pfizer Inc.
• Johnson & Johnson
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• AbbVie Inc.
• Bayer AG
• Novartis AG
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Sanofi S.A.
• GlaxoSmithKline PLC
• Eli Lilly and Company
• Amgen Inc.
• Koninklijke Philips N.V.
• Carl Zeiss AG
• Genentech Inc.
• Elekta Instrument AB
• Brainlab AG
• Optos Plc
• Castle Biosciences Inc.
• Heidelberg Engineering
• Nektar Therapeutics
• RaySearch Laboratories AB
• Nidek Co. Ltd.
• IDEAYA Biosciences
• Immunocore Limited
• Topcon Healthcare
• Oraya Therapeutics Inc.
• Delcath Systems Inc.
What Is The Most Dominant Region In The Eye Melanoma Market?
North America was the largest region in the eye melanoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eye melanoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
